hrcak mascot   Srce   HID

Izvorni znanstveni članak

Clinical significance of the malnutrition-inflammation-atherosclerosis syndrome in the patients on maintenance hemodialysis

Sanjin Rački ; Zavod za nefrologiju i dijalizu, Klinika za internu medicinu, Klinički bolnički centar Rijeka
Božidar Vujičić ; Zavod za nefrologiju i dijalizu, Klinika za internu medicinu, Klinički bolnički centar Rijeka
Ivan Bubić ; Zavod za nefrologiju i dijalizu, Klinika za internu medicinu, Klinički bolnički centar Rijeka
Ines Mrakovčić-Šutić ; Zavod za fiziologiju i imunologiju, Medicinski fakultet Sveučilišta u Rijeci
Petar Kes ; Zavod za nefrologiju, arterijsku hipertenziju i dijalizu, Klinika za unutarnje bolesti, Klinički bolnički centar Zagreb, Zagreb
Štefica Dvornik ; Klinički zavod za laboratorijsku dijagnostiku, KBC Rijeka
Žarko Mavrić ; Zavod za kardiovaskularne bolesti, Klinika za internu medicinu, KBC Rijeka
Luka Zaputović

Puni tekst: hrvatski, pdf (600 KB) str. 519-532 preuzimanja: 1.058* citiraj
APA 6th Edition
Rački, S., Vujičić, B., Bubić, I., Mrakovčić-Šutić, I., Kes, P., Dvornik, Š., ... Zaputović, L. (2010). Kliničko značenje sindroma pothranjenosti, upale i ateroskleroze u bolesnika na redovitoj hemodijalizi. Medicina Fluminensis, 46 (4), 519-532. Preuzeto s https://hrcak.srce.hr/63076
MLA 8th Edition
Rački, Sanjin, et al. "Kliničko značenje sindroma pothranjenosti, upale i ateroskleroze u bolesnika na redovitoj hemodijalizi." Medicina Fluminensis, vol. 46, br. 4, 2010, str. 519-532. https://hrcak.srce.hr/63076. Citirano 03.12.2021.
Chicago 17th Edition
Rački, Sanjin, Božidar Vujičić, Ivan Bubić, Ines Mrakovčić-Šutić, Petar Kes, Štefica Dvornik, Žarko Mavrić i Luka Zaputović. "Kliničko značenje sindroma pothranjenosti, upale i ateroskleroze u bolesnika na redovitoj hemodijalizi." Medicina Fluminensis 46, br. 4 (2010): 519-532. https://hrcak.srce.hr/63076
Harvard
Rački, S., et al. (2010). 'Kliničko značenje sindroma pothranjenosti, upale i ateroskleroze u bolesnika na redovitoj hemodijalizi', Medicina Fluminensis, 46(4), str. 519-532. Preuzeto s: https://hrcak.srce.hr/63076 (Datum pristupa: 03.12.2021.)
Vancouver
Rački S, Vujičić B, Bubić I, Mrakovčić-Šutić I, Kes P, Dvornik Š i sur. Kliničko značenje sindroma pothranjenosti, upale i ateroskleroze u bolesnika na redovitoj hemodijalizi. Medicina Fluminensis [Internet]. 2010 [pristupljeno 03.12.2021.];46(4):519-532. Dostupno na: https://hrcak.srce.hr/63076
IEEE
S. Rački, et al., "Kliničko značenje sindroma pothranjenosti, upale i ateroskleroze u bolesnika na redovitoj hemodijalizi", Medicina Fluminensis, vol.46, br. 4, str. 519-532, 2010. [Online]. Dostupno na: https://hrcak.srce.hr/63076. [Citirano: 03.12.2021.]

Sažetak
Objectives. To evaluate the clinical significance of the Malnutrition-Inflammation-
Atherosclerosis (MIA) syndrome as a cardiovascular risk factor in the maintenance hemodialysis
patients. Patients and Methods. 208 maintenance hemodialysis patients were assessed
at the Nephrology and Dialysis Department of the University Clinical Hospital Rijeka.
A total of 168 patients were analyzed. The diagnosis of MIA syndrome was established using
the MIA score assessed with appropriate scale and it was present in 66 patients. Two-year
mortality and morbidity was followed according to presence of MIA syndrome. Patients
with MIA syndrome were randomized into 4 groups and treated with atorvastatin, online
hemodiafiltation (OL-HDF), Helixone® membrane, and standard hemodialysis. The MIA syndrome
parameters were evaluated after follow-uP of 12 and 24 months. A statistical analysis
was performed using the appropriate tests using the statistical software MedCalc 7.5 (Med-
Calc, Mariakerke, Belgium). Results. Mean patients age was 63±13 years with equal gender
distribution. The most common underlying renal disease was chronic glomerulonephritis (31.0 %). The MIA syndrome was present in 39.3 % of patients.
Their mortality was significantly higher (36.4 % vs.
12.7 %, P = 0.0006). Causes of death did not differ according
to the presence of MIA syndrome. The most common cause
of death was cardiovascular disease (62.2 %). The patients
treated with atorvastatin, OL-HDF and Helixone® membrane
had better survival than patients treated with standard hemodialysis
(P = 0.0032). Independent mortality predictors in
the patients with MIA syndrome were not found. Treatment
with atorvastatin and OL-HDF significantly reduced serum Creactive
protein levels (P = 0.0161; P = 0.0425) and serum
interleukin-6 levels (P = 0.0005; P = 0.021) after 12 and 24
months, respectively. Conclusion. Atorvastatin, OL-HDF and
use of the new Helixone® membrane was beneficial in the
treatment of patients with MIA syndrome.

Ključne riječi
atherosclerosis; atorvastatin; cardiovascular diseases; cytokines; MIA syndrome; online hemodiafiltation

Hrčak ID: 63076

URI
https://hrcak.srce.hr/63076

[hrvatski]

Posjeta: 1.551 *